Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001493152-25-009108
Filing Date
2025-03-04
Accepted
2025-03-04 21:58:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6035
  Complete submission text file 0001493152-25-009108.txt   7934
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
Scinai Immunotherapeutics Ltd. (Subject) CIK: 0001611747 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89384 | Film No.: 25708569
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 3105 NW 107TH AVENUE SUITE 103 DORAL FL 33172
Business Address 3105 NW 107TH AVENUE SUITE 103 DORAL FL 33172 617-304-1099
LCK JNK 1 LLC (Filed by) CIK: 0002055074 (see all company filings)

EIN.: 332550030 | State of Incorp.: FL | Fiscal Year End: 1231
Type: SCHEDULE 13G/A